Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Study acronym: TRIO
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 9 months later Dec 31, 2026 → Oct 2028
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Chong Kun Dang Pharmaceutical

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Oct 2028 Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Start date: Mar 16, 2024 to Jan 2, 2024
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (5)
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Trial Details
NCT Number NCT06838286
Lead Sponsor Chong Kun Dang Pharmaceutical
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov